New landscape in the treatment of melanoma: A 2012 update

Oncologie

Volumn 15, Issue 2, 2013, Pages 71-77

  Eigentler, T K ^a   Garbe, C ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Adjuvant treatment; BRAF inhibitors; Immunotherapies; MEK inhibitors; Melanoma; Systemic treatment

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DACARBAZINE; GLYCOPROTEIN GP 100; INTERLEUKIN 2; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; PEGINTERFERON ALPHA2B; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; TRAMETINIB; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; CELL THERAPY; DRUG DOSE ESCALATION; DRUG MEGADOSE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; MELANOMA; OVERALL SURVIVAL; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE;

EID: 84882825158     PISSN: 12923818     EISSN: 17652839     Source Type: Journal    
DOI: 10.1007/s10269-013-2258-x     Document Type: Review

References (37)

1. Atkins MB, Hsu J, Lee S, et al. (2008) Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 26(35): 5748-5754
2. Brahmer JR, Tykodi SS, Chow LQ, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26): 2455-2465
3. Cameron DA, Cornbleet MC, MacKie RM, et al. (2001) Adjuvant interferon alpha 2b in high risk melanoma: the Scottish study. Br J Cancer 84(9): 1146-1149
4. Cascinelli N, Belli F, MacKie RM, et al. (2001) Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 358(9285): 866-869
5. Chapman PB, Hauschild A, Robert C, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26): 2507-2516
6. Eggermont AM, Suciu S, MacKie R, et al. (2005) Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366(9492): 1189-1196
7. Eggermont AM, Suciu S, Rutkowski P, et al. (2010) Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: final results of study EORTC 18961. J Clin Oncol 28(15s): (suppl.) Abstract: 8505
8. Eggermont AM, Suciu S, Santinami M, et al. (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372(9633): 117-126
9. Eggermont AM, Suciu S, Testori A, et al. (2012) Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 30(31): 3810-3818
10. Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4(12): 748-759
11. Erdmann F, Lortet-Tieulent J, Schuz J, et al. (2013) International trends in the incidence of malignant melanoma 1953-2008: are recent generations at higher or lower risk? Int J Cancer 132(2): 385-400
12. Flaherty KT, Puzanov I, Kim KB, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9): 809-819
13. Flaherty KT, Robert C, Hersey P, et al. (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2): 107-114
14. Garbe C, Blum A (2001) Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 14(5): 280-290
15. Grob JJ, Dreno B, de la Salmoniere P, et al. (1998) Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351(9120): 1905-1910
16. Grob JJ, Jouary T, Dreno B, et al. (2013) Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Eur J Cancer 49 (1): 166-174
17. Hancock BW, Wheatley K, Harris S, et al. (2004) Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 22(1): 53-61
18. Hauschild A, Grob JJ, Demidov LV, et al. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 380(9839): 358-365
19. Hauschild A, Weichenthal M, Rass K, et al. (2009) Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph nodenegative melanoma. J Clin Oncol 27(21): 3496-3502
20. Hodi FS, O'Day SJ, McDermott DF, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8): 711-723
21. Ives NJ, Stowe RL, Lorigan P, Wheatley K (2007) Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 25(34): 5426-5434
22. Kim CJ, Dessureault S, Gabrilovich D, et al. (2002) Immunotherapy for melanoma. Cancer Control 9(1): 22-30
23. Kirkwood JM, Ibrahim JG, Sondak VK, et al. (2000) High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/ C9190. J Clin Oncol 18(12): 2444-2458
24. Kirkwood JM, Ibrahim JG, Sosman JA, et al. (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19(9): 2370-2380
25. Kirkwood JM, Lee S, Moschos SJ, et al. (2009) Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colonystimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 15(4): 1443-1451
26. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14(1): 7-17
27. Mocellin S, Pasquali S, Rossi CR, Nitti D (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102(7): 493-501
28. Morton D, Mozillo N, Thompson J, et al. (2007) An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 25 (18s): (suppl.) Abstract: 8508
29. Parkinson DR, Abrams JS, Wiernik PH, et al. (1990) Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 8(10): 1650-1656
30. Pectasides D, Dafni U, Bafaloukos D, et al. (2009) Randomized phase III study of 1 month versus 1 year of adjuvant highdose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 27(6): 939-944
31. Pehamberger H, Soyer HP, Steiner A, et al. (1998) Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 16(4): 1425-1429
32. Robert C, Thomas L, Bondarenko I, et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26): 2517-2526
33. Rosenberg SA, Yang JC, Sherry RM, et al. (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13): 4550-4557
34. Schwartzentruber DJ, Lawson DH, Richards JM, et al. (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364 (22): 2119-2127
35. Sosman JA, Kim KB, Schuchter L, et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8): 707-714
36. Topalian SL, Hodi FS, Brahmer JR, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26): 2443-2454
37. Zarour HM, Kirkwood JM (2003) Melanoma vaccines: early progress and future promises. Semin Cutan Med Surg 22(1): 68-75